AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23101534 — intervention group
Group type: EXPERIMENTAL
Intervention: Handle position 2
Number of subjects: 50
Study 19950737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch (180 mg of diclofenac epolamine salt)
Number of subjects: 126
Study 19950737 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 126
Study 17325399 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age of self and partner at first intercourse
Number of subjects: 0
Study 17325399 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-use of contraception at first intercourse
Number of subjects: 0
Study 17325399 — intervention group
Group type: COMPARATOR
Intervention: Use of contraception at first intercourse
Number of subjects: 0
Study 17325399 — intervention group
Group type: EXPERIMENTAL
Intervention: Young partner at first intercourse
Number of subjects: 0
Study 15142019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity eccentric PRT (HRT)
Number of subjects: 37
Study 15142019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity eccentric PRT (LRT)
Number of subjects: 37
Study 15142019 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study 11566277 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 160 mg/g methyl 5-aminolevulinate for 3 hours
Number of subjects: 16
Study 11566277 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 16 mg/g methyl 5-aminolevulinate for 3 or 18 hours
Number of subjects: 16
Study 11566277 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 80 mg/g methyl 5-aminolevulinate for 3 or 18 hours
Number of subjects: 16
Study 9591168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain treatment program
Number of subjects: 0
Study 9591168 — intervention group
Group type: COMPARATOR
Intervention: Control group (fibromyalgia patients who failed to qualify for the treatment program)
Number of subjects: 0
Study 7886773 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin plus mefloquine
Number of subjects: 544
Study 7886773 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin alone for 5 d
Number of subjects: 544
Study 7886773 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin plus sulfadoxine-pyrimethamine (SP)
Number of subjects: 544
Study 7886773 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine-sulfadoxine-pyrimethamine (MSP)
Number of subjects: 544
Study 7886773 — intervention group
Group type: COMPARATOR
Intervention: Quinine plus sulfadoxine-pyrimethamine (SP)
Number of subjects: 544
Study 2980870 — intervention group
Group type: EXPERIMENTAL
Intervention: The Eating Machine software
Number of subjects: 0
Study 2980870 — intervention group
Group type: EXPERIMENTAL
Intervention: EATS software
Number of subjects: 0
Study 2980870 — intervention group
Group type: COMPARATOR
Intervention: Ferguson's behavioral program alone
Number of subjects: 0
Study 28926514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.003% estradiol vaginal cream (15 μg estradiol; 0.5 g cream) applied daily for 2 weeks followed by three applications/week for 10 weeks
Number of subjects: 550
Study 28926514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.003% estradiol vaginal cream
Number of subjects: 550
Study 28926514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 g cream)
Number of subjects: 550
Study 27286071 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused cognitive-behavioural therapy plus convergence dialogue meeting (CDM)
Number of subjects: 60
Study 27286071 — intervention group
Group type: COMPARATOR
Intervention: Work-focused cognitive-behavioural therapy without CDM
Number of subjects: 60
Study 25329643 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the stabilization device (MVSD)
Number of subjects: 0
Study 25329643 — intervention group
Group type: COMPARATOR
Intervention: Non-moving ambulance (NM)
Number of subjects: 0
Study 25329643 — intervention group
Group type: COMPARATOR
Intervention: Moving ambulance without device (MND)
Number of subjects: 0
Study 25329643 — intervention group
Group type: COMPARATOR
Intervention: Moving ambulance with device (MD)
Number of subjects: 0
Study 25329643 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 0
Study 23881566 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (100-1,000 μg)
Number of subjects: 36
Study 23881566 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (500 μg)
Number of subjects: 36
Study 23881566 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (1,000 μg)
Number of subjects: 36
Study 23881566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20528791 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation through group meetings at local health centres with health staff and community key persons
Number of subjects: 17519
Study 20528791 — intervention group
Group type: COMPARATOR
Intervention: Home deliveries without skilled attendance
Number of subjects: 17519
Study 18932120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Actively advised to apply for medical rehabilitation with individual risk information.
Number of subjects: 471
Study 18932120 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Received usual care.
Number of subjects: 471
Study 17054472 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 26
Study 17054472 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA withdrawal
Number of subjects: 26
Study 17054472 — intervention group
Group type: COMPARATOR
Intervention: Control group (male patients)
Number of subjects: 26
Study 12154110 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet (108 mmol/d NaCl)
Number of subjects: 12
Study 12154110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol/d NaCl)
Number of subjects: 12
Study 12154110 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro sodium concentrations (154 to 308 mmol/L)
Number of subjects: 12
Study 10195508 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural anesthesia (TEA)
Number of subjects: 70
Study 10195508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 70
Study 10195508 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anesthesia only)
Number of subjects: 70
Study 8560359 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nitrofurantoin macro-crystals 3 times daily for 7 days (Group A)
Number of subjects: 101
Study 8560359 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nitrofurantoin macro-crystals 4 times daily for 7 days (Group B)
Number of subjects: 101
Study 2127940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (1 gram of cefotetan)
Number of subjects: 266
Study 2127940 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 266
Study 536982 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric screening and surveillance
Number of subjects: 295
Study 31619441 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigs containing 50% propylene glycol and 50% vegetable glycerine
Number of subjects: 30
Study 31619441 — intervention group
Group type: COMPARATOR
Intervention: no-use control group
Number of subjects: 30
Study 31815651 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-filled balloon inserted above the main joint of the shoulder at the end of arthroscopic debridement
Number of subjects: 0
Study 31815651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive designs
Number of subjects: 0
Study 28371941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg/day
Number of subjects: 452
Study 28371941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 20 mg/day
Number of subjects: 452
Study 28371941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 30 mg/day
Number of subjects: 452
Study 28371941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin (all doses)
Number of subjects: 452
Study 28371941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 25863985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals consumed during four weeks
Number of subjects: 0
Study 24078432 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of fetal growth restriction (TRUFFLE trial)
Number of subjects: 503
Study 21419678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangerter filters (0.2 and 0.3 filters)
Number of subjects: 186
Study 19272597 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mL water intake
Number of subjects: 93
Study 19272597 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL water intake
Number of subjects: 93
Study 19272597 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL water intake
Number of subjects: 93
Study 19272597 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 17320555 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass
Number of subjects: 989
Study 17320555 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 989
Study 15328306 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg) administered 5 hours before exercise trial
Number of subjects: 8
Study 15328306 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 5 hours before exercise trial
Number of subjects: 8
Study 11887898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rholida
Number of subjects: 40
Study 11887898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 40
Study 11887898 — intervention group
Group type: EXPERIMENTAL
Intervention: Xi's capsule
Number of subjects: 40
Study 11887898 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 9557471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 800 mg i.v. slow infusion
Number of subjects: 297
Study 9557471 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g i.v.
Number of subjects: 297
Study 8231752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone immersion (WET)
Number of subjects: 12
Study 8231752 — intervention group
Group type: COMPARATOR
Intervention: Standing upright on land (DRY)
Number of subjects: 12
Study 3524439 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% tioconazole ointment
Number of subjects: 80
Study 3524439 — intervention group
Group type: COMPARATOR
Intervention: 100 mg clotrimazole vaginal tablets (3-day course)
Number of subjects: 80
Study 30067077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2s:4s (n = 18)
Number of subjects: 59
Study 30067077 — intervention group
Group type: EXPERIMENTAL
Intervention: 10s:10s (n = 20)
Number of subjects: 59
Study 30067077 — intervention group
Group type: EXPERIMENTAL
Intervention: 30s eccentric, 30s concentric, and 30s eccentric (e.g., 1.5 repetitions; n = 21)
Number of subjects: 59
Study 27545191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron and prednisone
Number of subjects: 0
Study 27545191 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron and prednisone (Control)
Number of subjects: 0
Study 25935645 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with topotecan and cisplatin
Number of subjects: 39
Study 25935645 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with consolidation chemotherapy (CCRT + CT)
Number of subjects: 39
Study 25935645 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 39
Study 22999784 — intervention group
Group type: COMPARATOR
Intervention: Extended Sprint (ES)
Number of subjects: 10
Study 22999784 — intervention group
Group type: COMPARATOR
Intervention: Sprint Interval Training (SIT)
Number of subjects: 10
Study 21640258 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg every 4 weeks during the fixed-dosing phase
Number of subjects: 159
Study 21640258 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (all groups combined)
Number of subjects: 159
Study 21640258 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (after 12-week fixed-dosing phase)
Number of subjects: 159
Study 21640258 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye
Number of subjects: 159
Study 19811592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of the misleading detail from the vignette
Number of subjects: 51
Study 19811592 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking doctors to identify a leading diagnostic detail and formulate an alternative diagnosis after omission of the detail
Number of subjects: 51
Study 19811592 — intervention group
Group type: COMPARATOR
Intervention: Warning doctors about potentially misleading information
Number of subjects: 51
Study 17034605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor muscle therapy (PFMT)
Number of subjects: 238
Study 17034605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cone therapy
Number of subjects: 238
Study 17034605 — intervention group
Group type: COMPARATOR
Intervention: Primary behavioral intervention (control)
Number of subjects: 238
Study 15165091 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc (5 g)
Number of subjects: 110
Study 15165091 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine (500 mg)
Number of subjects: 110
Study 11261275 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy (HDCT) with autologous stem cell transplantation
Number of subjects: 0
Study 11261275 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 9373483 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium
Number of subjects: 64
Study 9373483 — intervention group
Group type: COMPARATOR
Intervention: No diclofenac
Number of subjects: 64
Study 1535051 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 4 weeks)
Number of subjects: 33
Study 1535051 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 33
Study 4028987 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 0.1 mg doses of fenoterol each at 30 minute intervals
Number of subjects: 11
Study 4028987 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 0.4 mg fenoterol aerosol
Number of subjects: 11
Study 2441920 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 2441920 — intervention group
Group type: COMPARATOR
Intervention: Other DMARD
Number of subjects: 0
Study 31034350 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (G1)
Number of subjects: 50
Study 31034350 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (G2)
Number of subjects: 50
Study 31034350 — intervention group
Group type: COMPARATOR
Intervention: Comparison between G1 and G2 at one month
Number of subjects: 50
Study 27660163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly intravitreal injections of ranibizumab (IVR)
Number of subjects: 26
Study 27660163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly intravitreal injections of aflibercept (IVA)
Number of subjects: 26
Study 26312955 — intervention group
Group type: COMPARATOR
Intervention: Codeine/acetaminophen for 10 days post‐tonsillectomy (5 days scheduled, followed by 5 days as‐needed)
Number of subjects: 74
Study 26312955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol for 10 days post‐tonsillectomy (5 days scheduled, followed by 5 days as‐needed)
Number of subjects: 74
Study 23984631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive ability
Number of subjects: 138
Study 21504262 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth system with case management (THCM)
Number of subjects: 316
Study 21504262 — intervention group
Group type: COMPARATOR
Intervention: Case management (CM)
Number of subjects: 316
Study 21504262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 316
Study 18043495 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Noise Reduction (ANR) headphone audiometry
Number of subjects: 37
Study 18043495 — intervention group
Group type: COMPARATOR
Intervention: Standard audiometry
Number of subjects: 37
Study 16434130 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 148
Study 16434130 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination (control group)
Number of subjects: 148
Study 12921245 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 0.5 g every 8 hours as a 3-hour infusion
Number of subjects: 6
Study 12921245 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 2 g every 8 hours as a 3-hour infusion
Number of subjects: 6
Study 10866910 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + GBP (600 mg)
Number of subjects: 12
Study 10866910 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (60 mg) + GBP (600 mg)
Number of subjects: 12
Study 10866910 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 12
Study 10866910 — intervention group
Group type: COMPARATOR
Intervention: Morphine + placebo
Number of subjects: 12
Study 10866910 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine + GBP
Number of subjects: 12
Study 9378841 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of caffeine
Number of subjects: 12
Study 9378841 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of caffeine
Number of subjects: 12
Study 9378841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7505434 — intervention group
Group type: EXPERIMENTAL
Intervention: gammaglobulin 150 mg/kg x 2 on the first day of admission
Number of subjects: 54
Study 7505434 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 7505434 — intervention group
Group type: EXPERIMENTAL
Intervention: gammaglobulin 300 mg/kg/die for 3 days
Number of subjects: 54
Study 7505434 — intervention group
Group type: EXPERIMENTAL
Intervention: gammaglobulin 150 mg/kg/die during hospitalization
Number of subjects: 54
Study 3885107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 2-g dose at cord clamping
Number of subjects: 100
Study 3885107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31236976 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O (transobturator sling)
Number of subjects: 94
Study 31236976 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-S (single-incision sling)
Number of subjects: 94
Study 31236976 — intervention group
Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 94
Study 31236976 — intervention group
Group type: COMPARATOR
Intervention: TVT-S
Number of subjects: 94
Study 28241355 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel for 12 months
Number of subjects: 170
Study 28241355 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel for 12 months
Number of subjects: 170
Study 25732625 — intervention group
Group type: EXPERIMENTAL
Intervention: Beloranib 0.6 mg
Number of subjects: 147
Study 25732625 — intervention group
Group type: EXPERIMENTAL
Intervention: Beloranib 1.2 mg
Number of subjects: 147
Study 25732625 — intervention group
Group type: EXPERIMENTAL
Intervention: Beloranib 2.4 mg
Number of subjects: 147
Study 25732625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 23088807 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA810-1 (810-nm axial diode laser with 4-F introducer, 0.018" guidewire, 22-G needle)
Number of subjects: 60
Study 23088807 — intervention group
Group type: COMPARATOR
Intervention: RFA (ClosureFAST)
Number of subjects: 60
Study 23088807 — intervention group
Group type: EXPERIMENTAL
Intervention: EVLA1470 (1470-nm radial diode laser)
Number of subjects: 60
Study 22106845 — intervention group
Group type: EXPERIMENTAL
Intervention: Group relaxation training sessions according to the Yoga in Daily Life(®) system, plus audiocassette recordings for 3 weeks at home.
Number of subjects: 32
Study 22106845 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy for 1 week (control group).
Number of subjects: 32
Study 19142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber reformation with balanced salt solution and concurrent drainage of choroidal effusion
Number of subjects: 36
Study 19142129 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber reformation with viscoelastic substance
Number of subjects: 36
Study 19142129 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic therapy with atropine, phenylephrine, and in select cases oral acetazolamide
Number of subjects: 36
Study 18181342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at 80 mg/m2 and irinotecan at 200 mg/m2 on day 1, followed by docetaxel at 75 mg/m2 on day 22, in 6-week cycles for a maximum of 3 cycles.
Number of subjects: 24
Study 15383054 — intervention group
Group type: EXPERIMENTAL
Intervention: Contegra bovine valved jugular vein conduit
Number of subjects: 108
Study 12512683 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyaminopropyl biguanide (PHMB) -based system
Number of subjects: 50
Study 12512683 — intervention group
Group type: COMPARATOR
Intervention: Polyquad (polyquaternium-1) -based system
Number of subjects: 50
Study 9801234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular fixation
Number of subjects: 0
Study 9801234 — intervention group
Group type: COMPARATOR
Intervention: No fibular fixation
Number of subjects: 0
Study 8542099 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intermittent intravenous insulin therapy (CIIIT)
Number of subjects: 74
Study 8542099 — intervention group
Group type: COMPARATOR
Intervention: Intensive subcutaneous insulin therapy (ISIT) alone
Number of subjects: 74
Study 2477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-tip electrode (Siemens-Elema 412 S, tip material vitreous carbon)
Number of subjects: 79
Study 2477813 — intervention group
Group type: COMPARATOR
Intervention: Platinum-tip electrode (Siemens-Elema 415 S, tip material platinum)
Number of subjects: 79
Study 2477813 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-tip electrode
Number of subjects: 79
Study 2477813 — intervention group
Group type: COMPARATOR
Intervention: Platinum-tip electrode
Number of subjects: 79
Study 205687 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster immune plasma (ZIP)
Number of subjects: 20